Clinical Trial

A Study of GSM-779690T in Healthy Adult Participants

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase 1, single-centre, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple dose regimens of GSM-779690T in healthy adults. This first-in-human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSM-779690T.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-02.
Trial Details
NCT Number NCT07690228
Lead Sponsor Acta Pharmaceuticals
Conditions Healthy Adult Participants, Alzheimer Disease
Enrollment 72 participants
Start Date 2026-08-15
Primary Completion 2026-08-15 (estimated)
Study Completion 2027-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-09